

Cytosorbents Corp  
Form 8-K  
March 28, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): March 28, 2017

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-36792**

(Commission File Number)

**98-0373793**

(I.R.S. Employer Identification No.)

**7 Deer Park Drive, Suite K,**

**Monmouth Junction, New Jersey**

**08852**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 329-8885

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On March 28, 2017, CytoSorbents Corporation (the “Company”) announced the issuance of U.S. Patent No. 9,604,196 entitled, “Size Selective Hemocompatible Polymer System.”

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit No. Description.**

99.1 Press Release of the Company dated March 28, 2017.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 28, 2017 CYTOSORBENTS  
CORPORATION

By: /s/ Dr. Phillip P. Chan  
Name: Dr. Phillip P. Chan  
President and  
Title:  
Chief Executive Officer